CAM
MRSN

ClariVest Asset Management’s Mersana Therapeutics MRSN Stock Holding History

ClariVest Asset Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.01M Hold
20,020
– – 0.1% 260
2024
Q2 		$1.01M Buy
20,020
+1,146
+6% +$82.9K 0.1% 260
2024
Q1 		$2.11M Buy
+18,874
New +$1.88M 0.22% 127

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClariVest Asset Management's MRSN Position: Q3 2024 in Review

ClariVest Asset Management held its Mersana Therapeutics (MRSN) position steady in Q3 2024 at 20,020 shares worth $1.01M. The position accounts for 0.1% of the portfolio, ranked #260.

ClariVest Asset Management first reported a position in MRSN in Q1 2024 and has held it in 3 quarters since. The position peaked at $2.11M in Q1 2024. 113 funds tracked by Wall St. Rank hold MRSN as of Q3 2024.

  • ClariVest Asset Management held 20,020 shares of Mersana Therapeutics worth $1.01M as of Q3 2024.
  • ClariVest Asset Management left its Mersana Therapeutics share count unchanged in Q3 2024.
  • Mersana Therapeutics made up 0.1% of ClariVest Asset Management's portfolio in Q3 2024, its #260 holding.
  • ClariVest Asset Management first reported a position in Mersana Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • ClariVest Asset Management's Mersana Therapeutics position peaked at $2.11M in Q1 2024.
  • 113 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.